Central Venous Catheter Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Central Venous Catheter Market Trends and Insights

Rising Cancer, Dialysis, and Critical-Care Demand

The central venous catheter market continues to gain from cancer, dialysis, and critical care cases that require repeated access, reliable infusion, and controlled administration over extended treatment periods. Dialysis remains a key demand driver, as healthcare providers use tunneled catheters as bridging access when fistulas are not ready. Critical care also supports market growth, as patients in intensive care settings often need vasoactive drugs, blood products, monitoring, and nutritional support through a single access route. The overlap between oncology and kidney disease increases catheter use per patient when individuals require both chemotherapy and dialysis support. Public program expansion in countries such as India shows how higher service capacity can increase catheter placements in real care settings.

Increasing Preference for Power-Injectable Central Venous Catheters

Hospitals are increasingly adopting power-injectable systems as contrast-enhanced imaging becomes routine in cancer diagnosis, staging, and follow-up care. When catheters cannot support high-pressure contrast injection, clinicians often need an additional access step, which increases workload and patient inconvenience. Protocol-driven hospitals now treat power-injectable peripherally inserted central catheters (PICCs) and ports as standard specifications rather than optional premium upgrades. This shift benefits suppliers that combine catheter performance, insertion safety, and simplified workflow design in a single platform. BD’s CentroVena One launch reflects this direction, with a focus on integrated insertion, fewer procedural steps, and use in high-acuity environments.

Infection-Prevention Bundling and Chlorhexidine Adoption

Infection control remains a major factor shaping product selection in the central venous catheter market. Hospitals now assess standard and antimicrobial catheters within broader infection-prevention bundles that include insertion practices, dressing selection, barrier precautions, and coated devices. This approach makes premium catheter use easier to justify when infection reduction can be measured against reporting requirements and avoidable treatment costs. Teleflex reported a 70.5% reduction in central line-associated bloodstream infection (CLABSI) incidence in a multinational intensive care unit (ICU) cohort using Arrow chlorhexidine-impregnated catheters. This evidence supports broader formulary substitution and strengthens adoption across larger healthcare systems.

Longer Dwell-Time Use in Home Infusion and Ambulatory Settings

The central venous catheter market is gaining support from the shift toward decentralized care delivery. Patients receiving long-term antibiotics, parenteral nutrition, and repeated infusions are spending more treatment time outside traditional inpatient settings. This trend broadens demand for peripherally inserted central catheters (PICCs) and tunneled catheters that can remain in place for weeks or months without frequent replacement. APIC’s 2025 implementation guide will be important, as it extends infection-control focus beyond hospital central lines to outpatient and home vascular access. As surveillance, training, and securement practices improve, longer-dwell devices become easier to support at scale.

Catheter-Related Bloodstream Infection Risk

Infection risk continues to affect confidence in central access, despite stronger prevention protocols. The WHO’s 2024 guidance states that bloodstream infections associated with intravascular catheters require strict procedural discipline and continuous oversight. Hospitals also face reporting pressure, reimbursement consequences, and internal reviews when central line-associated bloodstream infection (CLABSI) events occur, extending the burden beyond clinical harm. Thrombosis adds further concern, as it can interrupt therapy, require catheter removal, and increase treatment costs for already fragile patients. A 2026 retrospective cohort study in BMC Surgery confirmed that tunneled non-cuffed centrally inserted catheters in oncology patients still carry meaningful thrombosis risk despite optimized placement protocols.^{[1]International Society of Nephrology, “Global Variations in Funding and Use of Hemodialysis Accesses, An International Report Using the ISN Global Kidney Health Atlas,” BMC Nephrology, link.springer.com} This restraint remains important for the central venous catheter market because safety concerns can slow adoption when buyers compare central access with less invasive options in selected cases.

Pricing Pressure from Value-Based Procurement and Tenders

Purchasing models that prioritize cost control and contract scale also restrain the central venous catheter market. In many regions, hospitals and public systems evaluate catheters through tenders, group purchasing organization (GPO) agreements, or multi-year contracting frameworks, which limit pricing flexibility for suppliers. These models make it harder for manufacturers to pass on the added costs of antimicrobial coatings, integrated insertion designs, or other premium features unless they clearly document outcome benefits. Teleflex’s 2025 Vizient contract illustrates how large contracting channels increasingly shape supplier access and favor vendors with established evidence and national reach. Smaller players may offer viable products, but they often lack the clinical documentation or contracting leverage needed to defend higher price points in large procurement systems. As a result, the central venous catheter market can grow in volume while still facing pressure on average selling prices.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Long-Term Oncology Needs Are Lifting Implanted Port Demand

Peripherally inserted central catheters (PICCs) are expected to account for 38.12% of the product type segment in 2025, maintaining the leading position across intermediate-duration therapies. Their use remains strong in antibiotic infusion, chemotherapy cycles, and treatments that require reliable access without immediate surgical implantation. Non-tunneled catheters support acute hospital needs, while tunneled devices remain important in dialysis and chronic oncology care. This mix keeps the central venous catheter market balanced between high-volume acute use and durable long-term access.

Implanted ports are projected to be the fastest-growing product category, registering a 9.53% compound annual growth rate (CAGR) from 2026 to 2031, driven by stronger demand in oncology and pediatric care. Their fully subcutaneous design improves patient comfort, lowers visibility, and supports extended treatment needs. Hybrid concepts, such as PICC-PORT designs, indicate a shift toward flexible access options for difficult anatomies. This category is gaining importance as suppliers pursue differentiation in high-value and long-dwell applications.

By Lumen Type: Procedure Complexity Is Supporting More Channels per Catheter

Double lumen catheters are expected to hold a 42.45% share in 2025, making them the leading lumen type across dialysis and multi-drug hospital protocols. Dialysis requires simultaneous withdrawal and return, while oncology and intensive care regimens benefit from separated channels. Single lumen devices support simpler therapies, and triple lumen configurations remain relevant in high-acuity care. Lumen selection in the central venous catheter market remains closely linked to treatment complexity.

Multi-lumen catheters are projected to be the fastest-growing lumen category, registering an 8.67% CAGR through 2031, as care pathways require more simultaneous infusions through fewer insertion sites. Fewer insertion points can reduce patient access burden and simplify complex hospital protocols. Innovation is also advancing lumen-level performance, including surfaces designed to reduce clot formation and support longer use. Suppliers that improve channel functionality without complicating insertion are likely to stay well positioned.

By Material: Polyurethane Continues to Set the Performance Standard

Polyurethane is expected to account for 60.66% of the material segment in 2025, making it the dominant choice across most mainstream device formats. Its performance profile supports kink resistance, pushability, in-body softening, and compatibility with power injection in many use cases. Silicone continues to add value in selected long-dwell and pediatric applications where softness and compliance matter. The market continues to favor materials that support procedural efficiency and patient tolerance.

Other materials, including newer polymer blends and coated formulations, remain innovation areas but have not matched polyurethane’s installed base or scale. Procurement trends continue to support polyurethane because it offers a familiar platform that can incorporate antimicrobial or surface-enhanced features without disrupting workflow. A 2024 retrospective real-world study reported a 99% success rate and a 0.8% adverse event rate for chlorhexidine-silver sulfadiazine-coated polyurethane central venous catheters in 384 patients. This evidence strengthens buyer confidence in polyurethane-based platforms.

By Application: Nutrition Support Is Expanding Faster Than the Base of Drug Delivery

Drug administration is expected to remain the largest application segment, with a 52.67% share in 2025, as chemotherapy, antibiotics, and biologics continue to depend on stable central access. Blood transfusion and diagnostics also generate steady demand, particularly in oncology-linked and critical care pathways. Medication delivery remains the most frequent and operationally important use case across settings. This large installed base gives suppliers a stable platform as faster-growing applications expand.

Fluid and nutrition administration is projected to be the fastest-growing application, registering a 9.67% CAGR through 2031, marking a shift in central venous catheter use. Home parenteral nutrition, intensive care unit (ICU) nutritional support, and discharge models that extend therapy beyond inpatient care are supporting growth. When patients leave hospitals with ongoing nutrition needs, demand shifts toward longer outpatient management. A 2026 prospective observational study reported that PICCs represented 43.5% of all central venous access device (CVAD) insertions in hospitalized patients and found higher appropriateness rates for CVADs than for peripheral devices.

By End User: Site-of-Care Change Is Widening the Demand Base

Hospitals are expected to hold a 70.34% share in 2025, keeping them as the leading end-user group in the central venous catheter market. Their dominance reflects the concentration of intensive care, oncology treatment, interventional radiology, and complex inpatient procedures in hospital settings. Hospitals also remain the main environment for first placement in acute and high-risk cases, giving them strong influence over initial device selection. Specialty clinics are gaining relevance as dialysis units and oncology infusion centers expand central-access capabilities.

Ambulatory surgery centers (ASCs) are projected to be the fastest-growing end-user segment, registering an 8.87% CAGR from 2026 to 2031, as reimbursement and workflow pressures move suitable procedures into lower-cost settings. This trend favors products that reduce procedural steps, accelerate placement, and standardize performance across frequent procedures. Home healthcare is also gaining visibility, although expansion depends on nursing capacity, training, and coverage conditions. Suppliers that serve hospitals, ASCs, and home-linked care with fewer procedural burdens should have a clearer path to share retention.

Geography Analysis

North America is expected to hold a 41.56% share in 2025, maintaining its position as the largest regional block in the central venous catheter market. Strong infection-control standards, established hospital accreditation requirements, and broad adoption of premium antimicrobial and power-injectable device types support the region’s leadership. The United States remains especially important, as clinical protocols, mature contracting channels, and strong demand for workflow-improving technologies support premium device adoption. Canada and Mexico contribute steady growth, while product differentiation is shifting toward insertion systems, securement, and integrated workflow design rather than basic catheter access alone.

Europe remains the second-largest geographic block in the central venous catheter market, supported by large oncology treatment programs and established dialysis networks in Germany, France, and the United Kingdom. Italy and Spain add incremental demand through aging demographics and expanding outpatient infusion capabilities. Regulatory expectations under the European Union Medical Device Regulation increase the burden for newer entrants, especially in coated and antimicrobial categories where sustained post-market clinical follow-up remains important. B. Braun’s 2025 results, expected to be published in 2026, are expected to show EUR 584 million in research and development spending, with an 11% year-on-year increase, underlining continued investment in connected infusion and vascular access capabilities.

Asia-Pacific is the fastest-growing region in the central venous catheter market, with a projected compound annual growth rate of 10.56% from 2026 to 2031. Hospital capacity expansion, a rising chronic disease burden, and stronger public investment in dialysis and cancer care infrastructure drive regional growth. India benefits from dialysis program expansion, which supports tunneled catheter placement where fistula-based access is not yet available. China is developing along two tracks, with multinational suppliers competing on premium performance in top-tier hospitals while domestic manufacturers remain active in cost-sensitive procurement channels.